CGM In-Vivo Sensor Characterization Patent Snapshot
The CGM in-vivo sensor characterization patent space is a nascent, highly concentrated niche: a single applicant, Allez Health Inc, holds all 7 patent families identified in scope. Activity emerged in 2021 and the field is still expanding on a multi-year basis, though annual volume has eased from its 2022 peak and the most recent years are further understated by publication lag.
Single-filer dominance in a nascent niche
Allez Health Inc is the sole ranked applicant, accounting for all 7 patent families in scope. The top five filers’ share of the ranked applicants visible in this query stands at 100%, reflecting a field that has not yet attracted a second identifiable participant.
There is no meaningful tier gap because there is only one tier: Allez Health holds an absolute position. No challenger or follower has appeared in the data.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Allez Health Inc | 7 |
Allez Health’s monopoly on this specific characterization niche implies either that the problem is tightly coupled to their proprietary sensor platform, or that broader players have addressed the same need under adjacent IPC classes not captured here. Engineers entering the space face a concentrated but very small prior-art evidence snapshot.
The most recent 18–24 months of filings are under-counted due to standard patent publication lag; the apparent absence of filings in 2024–2026 should not be read as a halt in activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity emerging since 2021 with technology fully concentrated in diagnostics
Two charts characterize the field: an annual filing trend that shows how the niche materialized starting in 2021, and a technology composition view that shows complete concentration in a single IPC branch.
Annual filing trend
Zero filings were recorded from 2017 through 2020. Activity began in 2021, peaked in 2022, and the recent three-year window sits 150% above the prior three-year window, confirming multi-year growth. Years 2024 onward appear flat due to publication lag and should not be interpreted as inactivity.
↗ Hover for values · click a bar to ask EurekaTechnology composition
All 7 patent families map to A61B (Diagnosis & Surgery), with no dispersion across other IPC classes. This concentration indicates that current protection is focused exclusively on the diagnostic instrumentation layer rather than signal processing, materials, or data analytics branches.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Sensor for a continuous biological monitor having …
A subcutaneous sensor for use with a continuous glucose monitor includes a working electrode and a reference electrode. The reference electrode comprises a reference substrate, an ion limiting layer over the reference substrate and a composition for releasing nitric oxide (NO). The composition has a NO release compound, a hydrophilic material and a… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Sensor for a continuous biological monitor having … | 1 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Allez Health Inc
Allez Health holds all 7 patent families in scope, all classified under A61B5 (Diagnosis & Surgery). The applicant momentum trend is marked as a new entrant, with 5 families filed in the recent window — consistent with a company building a foundational patent position from a standing start. Filing activity began in 2021 and peaked in 2022.
families: 7No challenger identified
No second applicant appears in the ranking data. The challenger position is vacant, meaning any organization with active R&D in CGM in-vivo sensor characterization that is not Allez Health is either filing under broader IPC classes, has not yet published, or is not yet filing patents. This is an unusually open competitive environment for a medical-device niche.
families: —Frequently asked questions
The evidence covers 7 patent families in scope. This is a very small corpus, reflecting either a tightly defined search boundary or a genuinely nascent area of specialized patent activity.
Allez Health Inc is the only ranked applicant and holds all 7 patent families identified in scope. No second filer appears in the data.
Filings were zero from 2017 through 2020. Activity began in 2021, with the highest single-year count recorded in 2022. The field is therefore less than five years old as a distinct patenting niche.
The field is classified as Growth. The recent three-year filing window sits 150% above the prior three-year window, confirming multi-year expansion. Annual volume has eased from the 2022 peak, and the most recent years are further understated by publication lag.
Filings have been made in the United States, Europe (EPO), and via the WIPO PCT route. The United States leads by record count. No filings in Asian jurisdictions are evident from the current evidence.
All 7 families fall under A61B (Diagnosis & Surgery). Adjacent branches such as signal-processing and health-informatics methods (e.g., G16H) and biocompatible sensor materials (e.g., A61L, C12Q) appear unrepresented in the corpus, making them observable gaps worth monitoring for R&D positioning.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.